The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Basilea Pharmaceutica's share price is CHF53.70.
Basilea Pharmaceutica's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF17.01. Hence, Basilea Pharmaceutica's PS Ratio for today is 3.16.
Good Sign:
Basilea Pharmaceutica Ltd stock PS Ratio (=3.2) is close to 1-year low of 2.93.
The historical rank and industry rank for Basilea Pharmaceutica's PS Ratio or its related term are showing as below:
XSWX:BSLN'
s PS Ratio Range Over the Past 10 Years
Min: 2.45 Med: 3.68 Max: 14.87
Current: 3.15
During the past 13 years, Basilea Pharmaceutica's highest PS Ratio was 14.87. The lowest was 2.45. And the median was 3.68.
XSWX:BSLN's PS Ratio is ranked better than 76.86% of 929
companies
in the Biotechnology industry
Industry Median: 9.64
vs XSWX:BSLN: 3.15
During the past 12 months, the average Revenue per Share Growth Rate of Basilea Pharmaceutica was 12.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 9.80% per year.
During the past 13 years, Basilea Pharmaceutica's highest 3-Year average Revenue per Share Growth Rate was 364.00% per year. The lowest was -32.60% per year. And the median was 15.20% per year.
Back to Basics: PS Ratio
Basilea Pharmaceutica (XSWX:BSLN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's PS Ratio distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Basilea Pharmaceutica's Share Price of today is CHF53.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF17.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Basilea Pharmaceutica (XSWX:BSLN) has a PS Ratio of 3.16 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Basilea Pharmaceutica and its competitors. This is 14% below median its historical median of 3.68. Over the past decade, Basilea Pharmaceutica's PS Ratio has ranged from 2.45 to 14.87. According to the industry distribution chart, Basilea Pharmaceutica ranks #215 out of 929 companies in the Biotechnology industry, placing it in the top 23.1%.
Is Basilea Pharmaceutica's PS Ratio too high?
Basilea Pharmaceutica's current PS Ratio of 3.16 is 14% below median its 10-year median of 3.68. Over the past 10 years, this metric has ranged from a low of 2.45 to a high of 14.87. The Biotechnology industry median PS Ratio is 9.64. Basilea Pharmaceutica's value of 3.16 is 67.2% below this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #215 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #215 out of 929 companies for PS Ratio. This places Basilea Pharmaceutica in the top 23% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.64. Basilea Pharmaceutica's value of 3.16 is 67.2% below this benchmark. Historically, Basilea Pharmaceutica's own PS Ratio has ranged from 2.45 to 14.87 over the past decade. While the company's 10-year median is 3.68 vs. the industry median of 9.64, Basilea Pharmaceutica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current PS Ratio of 3.16 is 67.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current PS Ratio is 3.16, which is 14% below median its own 10-year median of 3.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.57, compared to a current price of CHF53.70 — trading 6.7% below its estimated fair value. The current PS Ratio is 3.16, which is 14% below median its 10-year median of 3.68 and 67.2% below the Biotechnology industry median of 9.64. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current PS Ratio is 3.16 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF53.70 is trading 6.7% below its estimated GF Value™ of CHF57.57.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for XSWX:BSLN:
PS Ratio: 3.16 (14% below median its 10-year median of 3.68)
GF Value™: CHF57.57 vs. price of CHF53.70 (6.7% below fair value)
Industry Position: 67.2% below the Biotechnology median (#215 of 929)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score
Get the complete analysis for XSWX:BSLN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
